China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Update

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) saw a large decline in short interest in March. As of March 13th, there was short interest totaling 31,586 shares, a decline of 39.9% from the February 26th total of 52,570 shares. Approximately 3.4% of the shares of the stock are short sold. Based on an average trading volume of 26,742 shares, the days-to-cover ratio is presently 1.2 days.

China SXT Pharmaceuticals Trading Down 1.5%

NASDAQ:SXTC opened at $1.30 on Friday. China SXT Pharmaceuticals has a 12 month low of $1.27 and a 12 month high of $1,046.99. The stock has a 50 day moving average of $4.24 and a two-hundred day moving average of $141.38.

China SXT Pharmaceuticals (NASDAQ:SXTC) last announced its earnings results on Wednesday, December 31st. The company reported ($4.50) earnings per share (EPS) for the quarter. The business had revenue of $0.31 million for the quarter.

Institutional Trading of China SXT Pharmaceuticals

Several large investors have recently bought and sold shares of SXTC. XTX Topco Ltd acquired a new stake in China SXT Pharmaceuticals in the 4th quarter valued at about $36,000. Virtu Financial LLC boosted its holdings in shares of China SXT Pharmaceuticals by 107.5% during the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock worth $46,000 after purchasing an additional 15,013 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new position in shares of China SXT Pharmaceuticals during the 3rd quarter worth approximately $78,000. Hedge funds and other institutional investors own 5.02% of the company’s stock.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of China SXT Pharmaceuticals to a “sell” rating in a report on Saturday, February 7th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.